SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today provided business updates and financial results for the third quarter ended September 30, 2026.
“Iambic’s mission is to make better technology for better medicines, and we believe that the past several months showed that at work across every part of our business,” said Tom Miller, PhD, Co-Founder & CEO of Iambic. “At ESMO, our updated clinical data showed the intracranial activity and tolerability for IAM1363, and we are preparing to start a registrational trial in 2027, subject to regulatory approval. We submitted the IND and have received a Safe-to-Proceed Letter for a Phase 1/2 trial for IAM217, our second wholly owned and platform-discovered candidate, with an anticipated IND submission for IAM-C1, our CDK2/4 inhibitor, close behind. We launched Enchant v3, a huge advance in the core AI technology that underpins our molecular superintelligence platform, and AbbVie and Bayer each chose to bring our platform to bear on their own discovery work through new Iambic partnerships. Our IPO gives us the resources to advance our pipeline through major inflection points and to keep scaling the platform behind it.”
Summary of Business Highlights
Pipeline
Partnerships
Platform
Third Quarter 2026 Financial Results
Since 2024, Iambic has entered eight partnerships across technology, discovery and clinical development. We believe that collaborations with AbbVie, Bayer and Takeda this year reflect the growing industry demand for AI-driven drug discovery. YTD (through Q3 2026), collaboration revenue was approximately $24 million, while billings from collaborations were approximately $100 million; for the same period, Iambic’s total operating expenses were approximately $108 million and costs related to compute were less than $10 million. Although we expect research and development costs to increase as our clinical trials expand, we believe that our partnership payments highlight our operational discipline and have been an efficient way to fund the company while serving the industry with leading technologies.
Additional Corporate Updates
About Iambic
Iambic’s mission is to make better technology for better medicines. By utilizing molecular superintelligence – integrating proprietary AI with automated, scalable chemistry and biology experimentation – our platform is designed to address the totality of drug discovery and development. We believe the utility of our platform is demonstrated by the discovery of IAM1363, a novel drug candidate advanced to the clinic in approximately two years, along with a diverse preclinical pipeline. Our leading AI technologies include Enchant and NeuralPLexer for multimodal endpoint prediction, designed to improve the speed, precision, and success rates of drug discovery and clinical development. At Iambic, we are building an engine that is designed to power the future of medicine. For more information, visit iambic.ai.
Non-GAAP Financial Measures
We supplement our GAAP consolidated financial statements and GAAP financial measures with other financial measures, namely billings from collaborations. We define billings from collaborations as collaboration revenue plus the change in deferred revenue during the period. A reconciliation of billings from collaborations to collaboration revenue is provided in the table below. We believe that this non-GAAP financial measure provides additional insight into the ongoing economics of our business and reflects how we track and manage our business internally. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
Contacts
Media:
Amanda Guisbond
Head of Communications
amanda.guisbond@iambic.ai
Investors:
Tiao Guan
Head of Investor Relations
tiao.guan@iambic.ai
| Iambic Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Collaboration revenue | $ | 11,351 | $ | 4,692 | $ | 24,105 | $ | 8,621 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 34,104 | 23,057 | 91,253 | 55,991 | ||||||||||||
| General and administrative | 7,362 | 4,255 | 16,477 | 10,923 | ||||||||||||
| Total operating expenses | 41,466 | 27,312 | 107,730 | 66,914 | ||||||||||||
| Loss from operations | (30,115 | ) | (22,620 | ) | (83,625 | ) | (58,293 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest income | 2,000 | 1,161 | 5,432 | 3,735 | ||||||||||||
| Interest expense | (3 | ) | (4 | ) | (8 | ) | (13 | ) | ||||||||
| Change in fair value of convertible notes | (10,371 | ) | — | (10,371 | ) | — | ||||||||||
| Other income (expense), net | (21 | ) | 4 | (52 | ) | (52 | ) | |||||||||
| Total other income (expense), net | (8,395 | ) | 1,161 | (4,999 | ) | 3,670 | ||||||||||
| Loss before income taxes | (38,510 | ) | (21,459 | ) | (88,624 | ) | (54,623 | ) | ||||||||
| Income tax expense | — | — | (2 | ) | — | |||||||||||
| Net loss | $ | (38,510 | ) | $ | (21,459 | ) | $ | (88,626 | ) | $ | (54,623 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (8.52 | ) | $ | (5.24 | ) | $ | (20.37 | ) | $ | (13.34 | ) | ||||
| Weighted-average shares of common stock outstanding | 4,521,229 | 4,098,903 | 4,349,767 | 4,095,440 | ||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation adjustment | 3 | (9 | ) | 14 | 20 | |||||||||||
| Total comprehensive loss | $ | (38,507 | ) | $ | (21,468 | ) | $ | (88,612 | ) | $ | (54,603 | ) | ||||
| Iambic Therapeutics, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share data) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 252,034 | $ | 180,539 | ||||
| Accounts receivable and unbilled receivables | 55,803 | 1,317 | ||||||
| Prepaid expenses and other current assets | 8,091 | 1,734 | ||||||
| Total current assets | 315,928 | 183,590 | ||||||
| Restricted cash | 562 | — | ||||||
| Property and equipment, net | 9,031 | 4,834 | ||||||
| Right-of-use asset | 4,458 | 5,015 | ||||||
| Other assets | 2,110 | 1,579 | ||||||
| Total assets | $ | 332,089 | $ | 195,018 | ||||
| Liabilities, convertible preferred stock and stockholders’ deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,304 | $ | 3,322 | ||||
| Accrued expenses and other current liabilities | 25,049 | 10,990 | ||||||
| Operating lease liability, current | 743 | 672 | ||||||
| Deferred revenue, current | 45,770 | 11,305 | ||||||
| Total current liabilities | 75,866 | 26,289 | ||||||
| Operating lease liability, non-current | 4,145 | 4,788 | ||||||
| Deferred revenue, non-current | 50,300 | 9,081 | ||||||
| Convertible notes | 76,871 | — | ||||||
| Other non-current liabilities | 9 | 91 | ||||||
| Total liabilities | 207,191 | 40,249 | ||||||
| Commitments and contingencies | ||||||||
| Convertible preferred stock, $0.001 par value, 174,860,201 and 141,800,841 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 28,524,929 and 25,386,578 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively; liquidation preference of $395,287 and $342,517 as of September 30, 2026 and December 31, 2025, respectively | 394,035 | 341,332 | ||||||
| Stockholders’ deficit: | ||||||||
| Common stock, $0.001 par value; 231,640,552 and 185,438,918 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 4,639,882 and 4,208,550 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 4 | 4 | ||||||
| Additional paid-in capital | 14,627 | 8,589 | ||||||
| Accumulated other comprehensive income | 38 | 24 | ||||||
| Accumulated deficit | (283,806 | ) | (195,180 | ) | ||||
| Total stockholders’ deficit | (269,137 | ) | (186,563 | ) | ||||
| Total liabilities, convertible preferred stock and stockholders’ deficit | $ | 332,089 | $ | 195,018 | ||||
| Iambic Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Collaboration revenue | $ | 11,351 | $ | 4,692 | $ | 24,105 | $ | 8,621 | ||||||||
| Add: Change in deferred revenue | 42,508 | (3,038 | ) | 75,684 | 10,376 | |||||||||||
| Billings from collaborations | $ | 53,859 | $ | 1,654 | $ | 99,789 | $ | 18,997 | ||||||||
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. Words such as “anticipate,” “believe,” “continue,” “could,” “designed,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to: statements regarding the potential therapeutic benefit, safety, tolerability, durability of response and differentiation of IAM1363, IAM217 and IAM-C1; statements regarding the design, timing and objectives of ongoing and planned clinical trials, including the planned registrational trial of IAM1363 and its anticipated timing; statements addressing the planned Phase 1/2 trials of IAM217 and IAM-C1, the timing of the IND submission for IAM-C1, and the timing and outcome of interactions with the FDA and other regulatory authorities; statements about the timing of wholly owned programs entering the discovery portfolio; statements about planned scientific presentations and about the capabilities, performance and continued improvement of Enchant, NeuralPLexer and our platform; statements regarding the timing of our move to our new headquarters and our planned use of the expanded laboratory space; statements regarding the progress of, potential benefits of, and payments under, our collaborations, including milestones and royalties; statements regarding our pro forma cash and cash equivalents position and the sufficiency of our capital resources to advance our pipeline; our expectations regarding research and development and other expenses; and the extent to which payments under our partnerships and collaborations may continue to fund our operations. These statements are based on management’s current expectations and assumptions and are subject to substantial risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied. These and other risks are described more fully under “Risk Factors” in Iambic’s final prospectus relating to its initial public offering filed with the Securities and Exchange Commission pursuant to Rule 424(b) on October 14, 2026, Iambic’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to be filed with the Securities and Exchange Commission, and in Iambic’s subsequent filings with the Securities and Exchange Commission.
The forward-looking statements in this press release speak only as of the date of this press release, and you should not rely on them as representing Iambic’s views as of any subsequent date. Iambic undertakes no obligation to update these forward-looking statements, or the reasons actual results could differ from those projected, except as required by law.